Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week comparison of fluticasone furoate + vilanterol versus tiotropium in COPD with cardiovascular risk
2011-002451-33Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone, vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline trough in 24-hour weighted-mean serial FEV1 at week 12. Started Apr 2012; status: completed.
02
Drugs
fluticasonevilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-002451-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002451-33.